160 related articles for article (PubMed ID: 33178990)
1. Role of tumor microenvironment in the efficacy of BCG therapy.
Ibrahim OM; Pandey RK; Chatta G; Kalinski P
Trends Res; 2020 Oct; 3(4):. PubMed ID: 33178990
[TBL] [Abstract][Full Text] [Related]
2. NFκB-Activated COX2/PGE
Ibrahim OM; Basse PH; Jiang W; Guru K; Chatta G; Kalinski P
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809455
[TBL] [Abstract][Full Text] [Related]
3. Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response.
Annels NE; Simpson GR; Pandha H
Front Oncol; 2020; 10():175. PubMed ID: 32133299
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?
Martins-Lima C; Chianese U; Benedetti R; Altucci L; Jerónimo C; Correia MP
Front Mol Biosci; 2022; 9():1070383. PubMed ID: 36699696
[TBL] [Abstract][Full Text] [Related]
5. CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes.
Liu Y; Wu Y; Zhang P; Xu C; Liu Z; He C; Liu Y; Kang Z
Front Oncol; 2021; 11():636870. PubMed ID: 33747959
[TBL] [Abstract][Full Text] [Related]
6. Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.
Rentsch CA; Derré L; Dugas SG; Wetterauer C; Federer-Gsponer JR; Thalmann GN; Ingersoll MA
Eur Urol Focus; 2018 Jul; 4(4):485-493. PubMed ID: 30415921
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
[TBL] [Abstract][Full Text] [Related]
8. AIM2 inflammasome activation benefits the therapeutic effect of BCG in bladder carcinoma.
Zhou H; Zhang L; Luo W; Hong H; Tang D; Zhou D; Zhou L; Li Y
Front Pharmacol; 2022; 13():1050774. PubMed ID: 36386141
[TBL] [Abstract][Full Text] [Related]
9. Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.
Wang Y; Yang M; Yu Q; Yu L; Shao S; Wang X
Expert Rev Anticancer Ther; 2015 Jan; 15(1):85-93. PubMed ID: 25231670
[TBL] [Abstract][Full Text] [Related]
10. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
[TBL] [Abstract][Full Text] [Related]
12. Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.
Zheng YQ; Naguib YW; Dong Y; Shi YC; Bou S; Cui Z
Expert Rev Vaccines; 2015; 14(9):1255-75. PubMed ID: 26268434
[TBL] [Abstract][Full Text] [Related]
13. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
14. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
Poletajew S; Zapała P; Radziszewski P
Urol Int; 2017; 99(1):1-5. PubMed ID: 28601885
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis.
Wu C; Zhou X; Miao C; Zhang J; Tang Q; Chang X; Ni H
Cell Physiol Biochem; 2017; 41(4):1298-1312. PubMed ID: 28278504
[TBL] [Abstract][Full Text] [Related]
17. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
[TBL] [Abstract][Full Text] [Related]
18. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
19. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
20. Intravesical immunotherapy in nonmuscle invasive bladder cancer.
Jokisch JF; Karl A; Stief C
Indian J Urol; 2015; 31(4):304-11. PubMed ID: 26604441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
